Adaptive trial of personalized radiotherapy for intrahepatic cancer

作者：Normolle Daniel^*; Pan Charlie; Ben Josef Edgar; Lawrence Theodore

来源：Personalized Medicine, 2010, 7(2): 197-204.

DOI：10.2217/PME.10.5

• adaptive trial design
• hepatocellular carcinoma
• indocyanine green
• radiation-induced liver disease
• radiofrequency ablation
• stereotactic body radiation therapy
• transarterial chemoembolization

Primary liver cancer is a major health problem worldwide, with more than 500,000 new cases diagnosed yearly. Preliminary results suggest excellent local control rates of intrahepatic malignancies treated with stereotactic body radiation therapy (SBRT), but some patients have experienced life-threatening toxicity because the current approaches cannot accurately estimate residual liver function after treatment. An early-phase trial of SBRT in hepatocellular carcinoma patients, including those with compromised liver function, is described. Patients are treated with three fractions of SBRT, then treatment is paused for 4 weeks and liver function is evaluated by means of an indocyanine green assay. The size of the final two fractions of SBRT is determined based on the patient's indocyanine green assay after the first three fractions, so that the therapy is personalized to each patient's sensitivity to radiation. The sensitivity to the liver of the final two fractions of SBRT, compared with the first three fractions, is re-estimated using a Bayesian model throughout the trial, so this is an adaptive trial. The operating characteristics of the trial are described by Monte Carlo simulations.

• 出版日期2010-3